Neha Krishnamohan sold $939k of ARQT
director at Arcutis Biotherapeutics, Inc.. 40,504 shares at an average of $23.20, traded Nov 13, 2025, filed Nov 17, 2025.
Score components
- +15RoleDirector
- +24Trade size$939k at market
- +20Share of holdings soldSold 65% of holdings
- +15Cluster9 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001866171-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 13, 2025 | MOption exercise Common Stock10b5-1 | +27,052 | $8.63 | $233k | 50,407 | Nov 17, 2025 |
| Nov 13, 2025 | MOption exercise Common Stock10b5-1 | +12,220 | $7.51 | $92k | 62,627 | Nov 17, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -39,272 | $23.19 | $911k | 23,355 | Nov 17, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -1,232 | $23.37 | $29k | 22,123 | Nov 17, 2025 |
| Nov 13, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -27,052 | $0.00 | $0 | 0 | Nov 17, 2025 |
| Nov 13, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -12,220 | $0.00 | $0 | 0 | Nov 17, 2025 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 28Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $257k 10,000 shares | -17% | |
| 40Moderate | Arcutis Biotherapeutics, Inc. | Keith R Leonard director | $997k 39,272 shares | -64% | |
| 21Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $158k 6,287 shares | -5% | |
| 25Weak | Arcutis Biotherapeutics, Inc. | Latha Vairavan SVP Chief Financial Officer | $72k 2,853 shares | -3% | |
| 24Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $314k 12,058 shares | -8% | |
| 34Weak | Arcutis Biotherapeutics, Inc. | Todd Watanabe See Remarks | $941k 37,349 shares | -5% | |
| 20Weak | Arcutis Biotherapeutics, Inc. | Larry Todd Edwards See Remarks | $93k 3,687 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.